A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

Trial Details

NCT ID
NCT07546500
Phase
PHASE3
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Investigator's choice of Chemotherapy
  • Azenosertib
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Antioch, California, United States|38.00492,-121.80579
  • San Francisco, California, United States|37.77493,-122.41942
  • Camden, New Jersey, United States|39.92595,-75.11962
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Female age ≥ 18 years
  • High-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
  • Measurable disease per RECIST Version 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →